August 13, 2012
I confess…I have been a bit lackadaisical in my scanning through the journals I receive each month. This point was driven home to me yesterday when I went to find room on my desk to put some work and realized it was totally covered with stacks of journal back issues I had put aside with all good intentions to eventually read through! It was time to start clearing my desk with the side benefit of realizing I could probably come up with some interesting articles to blog about. Well, I did. In fact, I think I have enough for a few upcoming posts. Those of you who have heard me lecture on MRSA know that I am not a big fan of the use of trimethoprim/sulfamethoxazole for the treatment of even mild outpatient infections. My main objection has been increased toxicity of this drug vs. other options including; Stevens-Johnson syndrome, renal toxicity, allergies, drug-drug interactions, etc. However, I have also questioned the evidence supporting its use and have frequently stated that we don’t even know the proper dosing! Most clinicians use this drug at the “standard” dose of 1 DS tablet bid (160mg/800mg). However, some authorities have argued that that dose is too low for MRSA and an increased dose of 2 DS tabs bid should be used. This has always concerned me because of the potential risk for increased adverse events with the higher dose. A study published in the December 2011 (I told you I was behind on my reading!) Clinical Infectious Diseases by Cadena and colleagues compared the two dosing regimens and found no difference in outcomes with those treated with the higher dose vs.
Read the full article →
May 22, 2012
As promised, I would post a link to the newly revised, updated IDSA DFI Guidelines as soon as they were available. Well, I am honored, proud and excited to be able to let my readership know that after about 6 years in writing, multiple levels of peer review and well over 60 individual review comments, that the newly revised guidelines have been posted by IDSA on their website. Here is the link: http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/PDF_Library/2012%20Diabetic%20Foot%20Infections%20Guideline.pdf Those of you familiar with the 2004 document will immediately notice the changes. All IDSA Guidelines are now standardized to a “question, recommendation, evidence summary” format. Each committee is assigned to determine which are the most critical questions that need to be answered. In this case, we came up with 10 questions that cover everything from diagnosis to antibiotics, to osteomyelitis and wound care. There are 44 evidenced based recommendations that guide the clinician in the answers to those 10 questions. The evidence is then summarized and graded by the British Medical Journal “GRADE” system. This common sense approach matches the strength of the recommendation with the level of the evidence. This is given in plain English. For example “Strong, Low” means that there is a strong recommendation but a relatively low level of evidence on which the decision has been based. I hope that you all find the new Guidelines helpful in your management of these patients. I look forward to your comments
Read the full article →